Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LSALT Peptide in Healthy Participants
NCT03772678Phase 1Completed
- Sponsor
- Arch Biopartners
- Start
- Jun 2019
- Primary completion
- Mar 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LSALT peptide in acute kidney injury (AKI) and acute respiratory distress syndrome (ARDS) (4 arms), sponsored by Arch Biopartners. Primary endpoint: Safety Evaluation at 21 days. Started Jun 2019; status: completed.
02
Drugs
LSALT peptide
03
Conditions
acute kidney injury (AKI)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT03772678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03772678.